AIM ImmunoTech Inc.
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
AIM$0.16+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description |
| 3.1 | Certificate of Incorporation as Amended and Restated through June 10, 2025 (incorporated by reference to Exhibit 3.1(i) to the Company’s Current Report on Form 8-K filed with the SEC on October 29, 2025). |
| 3.2 | Amended and Restated By-Laws of Registrant (incorporated by reference to Exhibit 3.7(ii) to the Company’s Current Report on Form 8-K filed with the SEC on February 26, 2025). |
| 3.3 | Certificate of Designation of Series G Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 6, 2026). |
| 3.4 | Amendment to the Company’s Amended and Restated By-Laws dated June 9, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 10, 2026). |
| 10.1 | Amendment to Equity Distribution Agreement with Maxim Group, LLC dated April 10, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 10, 2026). |
| 10.2 | Amendment #2 to Promissory Note with Streeterville Capital, LLC dated May 18, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on May 19, 2026). |
| 10.3 | Placement Agency Agreement with Ladenburg Thalman & Co, Inc dated May 20, 2026 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on May 21, 2026). |
| 10.4 | Security Purchase Agreement with Institution Investors dated June 9, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 11, 2026). |
| 10.5 | Placement Agency Agreement with Ladenburg Thalmann dated June 9, 2026 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 11, 2026). |
| 10.6 | Amendment to the Company’s Amended and Restated By-Laws dated June 9, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 10, 2026). |
| 10.7 | Mutual Termination of Controlled Equity Distribution Agreement dated April 1, 2025 effective August 15,2026 signed July 31, 2026 with Maxim Group, LLC*# |
| 10.8 | Proposal to GMP Manufacture Poly I and Poly C12U with Sterling Pharma Solutions dated July 31, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on August 6, 2026). |
| 31.1 | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer. * |
| 31.2 | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer. * |
| 32.1 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer. ** |
| 32.2 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer. ** |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| * | Filed herewith. |
| ** | The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission. |
| # | Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) are the type that the Company treats as private or confidential. The Company hereby agrees to furnish a copy of any redacted portion to the SEC upon request. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AIM IMMUNOTECH INC.
/s/ Thomas K. Equels
Thomas K. Equels, Esq.
Chief Executive Officer & President
/s/ Robert Dickey IV
Robert Dickey IV
Chief Financial Officer
Date: August 7, 2026
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.